logo
Share SHARE
FONT-SIZE Plus   Neg

Merck Launches NEXPLANON 68 Mg In U.S.

Merck & Co. (MRK) said Wednesday that NEXPLANON 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States.
NEXPLANON is approved by the FDA for the prevention of pregnancy in women for up to three years.

NEXPLANON must be removed by the end of the third year and may be replaced by a new NEXPLANON, if continued contraceptive protection is desired.

About the size of a matchstick, NEXPLANON is made of a soft, flexible, medical polymer and is inserted just under the skin of a woman's upper arm in a minor surgical in-office procedure.

NEXPLANON is effective, when inserted correctly, with less than 1 pregnancy per 100 women who used NEXPLANON for 1 year. NEXPLANON may be less effective in women who are very overweight and in women who are taking medications that induce liver enzymes. NEXPLANON is a progestin-only contraceptive that does not contain estrogen. NEXPLANON does not depend on daily, weekly, monthly, or quarterly administration. Etonogestrel, the progestin in NEXPLANON, prevents pregnancy in three ways: inhibiting ovulation, thickening of the cervical mucus, and alterations in the endometrium.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
International Consolidated Airlines Group S.A. Friday reported profit for the first quarter, compared to loss in the prior year, mainly reflecting higher passenger revenues and increased capacity. For fiscal 2016, IAG still expects to generate an absolute operating profit increase similar to 2015 as it expects to reduce underlying ex-fuel unit costs by around one percent. French drug maker Sanofi reported Friday a higher profit in its first quarter, while net sales were hurt mainly by weak results in Diabetes unit and Venezuela. Excluding Venezuela. Aggregate Group sales increased 3 percent at constant exchange rates. Looking ahead, the company continues to expect 2016 business earnings per share to be broadly stable at CER. LinkedIn Corp. (LNKD) on Thursday posted a loss for the first-quarter that widened from a year ago, hurt largely by higher operating costs. On an adjusted basis, earnings for the quarter improved and trumped Wall Street estimates, as revenues jumped 35 percent led by growth across all segments. Shares...
comments powered by Disqus
Follow RTT